Hypermarcas (HYPMY) to Release Quarterly Earnings on Wednesday

Posted by Bonnie Powley on Jul 29th, 2026

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) is expected to announce its results after the market closes on Wednesday, August 5th. Analysts expect Hypermarcas to post earnings of $0.14 per share and revenue of $466.4080 million for the quarter.

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 EPS for the quarter. The firm had revenue of $383.13 million for the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. On average, analysts expect Hypermarcas to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hypermarcas Price Performance

Shares of HYPMY opened at $4.15 on Wednesday. The company has a market capitalization of $2.92 billion, a P/E ratio of 8.65 and a beta of 0.71. The firm has a 50 day moving average of $4.13 and a 200 day moving average of $4.38. Hypermarcas has a twelve month low of $3.71 and a twelve month high of $5.50.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Zacks Research upgraded Hypermarcas to a “hold” rating in a research note on Wednesday, April 29th. Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

View Our Latest Stock Analysis on Hypermarcas

Hypermarcas Company Profile

(Get Free Report)

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.